SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting
06 nov. 2023 08h57 HE
|
SELLAS Life Sciences Group, Inc.
Median overall survival for GPS and Keytruda® combination was 18.4 Months compared to 13.8 Months in a Keytruda® single agent study (KEYNOTE-028) and 11-14 Months with standard of care...
SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
31 oct. 2023 08h05 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas
30 oct. 2023 09h03 HE
|
SELLAS Life Sciences Group, Inc.
- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL Patients with Standard of Care is 25.8% - -...
SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting
17 oct. 2023 08h45 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia
16 oct. 2023 08h45 HE
|
SELLAS Life Sciences Group, Inc.
– SLS009 Is First CDK9 Inhibitor in Combination with AZA/VEN to Achieve Complete Response in AML Patient Resistant to Venetoclax Combination Therapies – – First Patient Enrolled Achieved CR and...
SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia
12 oct. 2023 16h05 HE
|
SELLAS Life Sciences Group, Inc.
- Enrollment ex-China Expected to be Completed in November 2023 – - Enrollment in China Expected to Commence this Quarter - NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group,...
SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas
11 oct. 2023 08h30 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia
10 oct. 2023 16h15 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met
21 sept. 2023 08h30 HE
|
SELLAS Life Sciences Group, Inc.
- 52 Relapsed and Refractory Lymphoma Patients Enrolled: 96% Alive at Last Assessment Indicating Favorable Survival Benefit - - Responses Observed Across Dose Levels with a 14.7% Clinical Response...
SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference
18 sept. 2023 16h19 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...